臨床泌尿器科70巻7号

2016年06月発行

特集 進行期精巣腫瘍の診療─難治症例に挑む

〈導入化学療法で寛解が得られない症例への対処〉

二次以降の大量化学療法

著者： 河野勤¹

所属機関： ¹公益財団法人佐々木研究所附属杏雲堂病院腫瘍内科

ページ範囲：P.506 - P.517

文献概要

▶ポイント

・導入化学療法で腫瘍マーカーが正常化せずプラトーに達するケースでは，本邦と欧米では救援化学療法の考え方が異なる．

・欧米では“platinum-refractory”（最終化学療法終了後4週未満での増悪）例や複数回の再発・再燃例など標準量の救援化学療法で完治が期待しにくいケースに対して，末梢血幹細胞移植を併用した大量化学療法が試みられている．

・欧米の代表的施設の間でも大量化学療法の適応とする患者および用いるレジメンには相違がある．

参考文献

1） Zon RT, Nichols C and Einhorn LH : Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 16 : 1294─1297, 1998

2） Nichols CR, Tricot G, Williams SD, et al : Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7 : 932─939, 1989

3） Einhorn LH : Salvage therapy in patients with germ cell tumors. Am Soc Clin Oncol Educ Book 35 : e259─261, 2015

4） Beyer J, Kramar A, Mandanas R, et al : High-dose chemotherapy as salvage treatment in germ cell tumors : a multivariate analysis of prognostic variables. J Clin Oncol 14 : 2638─2645, 1996

5） Lorch A, Beyer J, Bascoul-Mollevi C, et al : Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28 : 4906─4911, 2010

6） Simonelli M, Rosti G, Banna GL, et al : Intensified chemotherapy with stem-cell rescue in germ-cell tumors. Ann Oncol 23 : 815─822, 2012

7） Lorch A, Bascoul-Mollevi C, Kramar A, et al : Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors : evidence from a large international database. J Clin Oncol 29 : 2178─2184, 2011

8） Loehrer PJ, Einhorn LH and Williams SD : VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 4 : 528─536, 1986

9） Loehrer PJ Sr, Gonin R, Nichols CR, et al : Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16 : 2500─2504, 1998

10） Nichols CR, Andersen J, Lazarus HM, et al : High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer : an Eastern Cooperative Oncology Group protocol. J Clin Oncol 10 : 558─563, 1992

11） Broun ER, Nichols CR, Kneebone P, et al : Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117 : 124─128, 1992

12） Broun ER, Nichols CR, Tricot G, et al : High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Bone Marrow Transplant 7 : 53─56, 1991

13） Broun ER, Nichols CR, Turns M, et al : Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 73 : 1716─1720, 1994

14） Broun ER, Nichols CR, Gize G, et al : Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 79 : 1605─1610, 1997

15） Bhatia S, Abonour R, Porcu P, et al : High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18 : 3346─3351, 2000

16） Vaena DA, Abonour R and Einhorn LH : Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 21 : 4100─4104, 2003

17） Einhorn LH, Williams SD, Chamness A, et al : High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357 : 340─348, 2007

18） Siegert W, Beyer J, Strohscheer I, et al : High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer : a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 12 : 1223─1231, 1994

19） Rick O, Beyer J, Kingreen D, et al : High-dose chemotherapy in germ cell tumours : a large single centre experience. Eur J Cancer 34 : 1883─1888, 1998

20） Beyer J, Schwella N, Zingsem J, et al : Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow : a randomized comparison. J Clin Oncol 13 : 1328─1335, 1995

21） Pico JL, Rosti G, Kramar A, et al : A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16 : 1152─1159, 2005

22） Rick O, Bokemeyer C, Beyer J, et al : Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19 : 81─88, 2001

23） Lorch A, Kollmannsberger C, Hartmann JT, et al : Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors : a prospective randomized multicenter trial of the german testicular cancer study group. J Clin Oncol 25 : 2778─2784, 2007

24） Lorch A, Kleinhans A, Kramar A, et al : Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors : long-term results of a prospective randomized trial. J Clin Oncol 30 : 800─805, 2012

25） Motzer RJ, Gulati SC, Crown JP, et al : High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer 69 : 550─556, 1992

26） Motzer RJ, Mazumdar M, Bosl GJ, et al : High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors : treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14 : 1098─1105, 1996

27） Feldman DR, Sheinfeld J, Bajorin DF, et al : TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors : results and prognostic factor analysis. J Clin Oncol 28 : 1706─1713, 2010

28） Einhorn LH, Abonour R and Kesler KA : Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide for patients with relapsed primary mediastinal nonseminomatous germ cell tumors : benefit from chemotherapy, surgery, or both? J Clin Oncol 28 : e739, 2010

29） Radaideh SM, Cook VC, Kesler KA, et al : Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy. Ann Oncol 21 : 804─807, 2010

30） Feldman DR, Glezerman I, Patil S, et al : Phase I/II trial of paclitaxel with ifosfamide followed by high-dose paclitaxel, ifosfamide, and carboplatin （TI-TIC） with autologous stem cell reinfusion for salvage treatment of germ cell tumors. Clin Genitourin Cancer 13 : 453─460, 2015

31） Feldman DR, Huddart R, Hall E, et al : Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. J Cancer 2 : 374─377, 2011

32） Lotz JP, Machover D, Malassagne B, et al : Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. J Clin Oncol 9 : 1860─1870, 1991

33） Lotz JP, André T, Donsimoni R, et al : High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 75 : 874─885, 1995

34） Pico JL, Ibrahim A, Castagna L, et al : Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors. Oncology 50 : 47─52, 1993

35） Lotz JP, Bui B, Gomez F, et al : Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol 16 : 411─418, 2005

36） Selle F, Wittnebel S, Biron P, et al : A Phase II trial of high-dose chemotherapy （HDCT） supported by hematopoietic stem cell transplantation （HSCT） in germ-cell tumors （GCTs） patients failing cisplatin-based chemotherapy : the multicentric TAXIF II study. Ann Oncol 25 : 1775─1782, 2014

37） Nieto Y, Shpall EJ, Bearman SI, et al : Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Biol Blood Marrow Transplant 11 : 297─306, 2005

38） Nieto Y, Aldaz A, Rifón J, et al : Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. Biol Blood Marrow Transplant 13 : 1324─1337, 2007

39） Nieto Y, Tu SM, Bassett R, et al : Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol 26 : 2125─2132, 2015